Login / Signup

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.

Bixia TangXieqiao YanXinan ShengLu SiChuanliang CuiYan KongLili MaoBin LianXue BaiXuan WangSiming LiLi ZhouJiayi YuJie DaiKai WangJinwei HuLihou DongHaifeng SongHai WuHui FengSheng YaoZhihong ChiJun Guo
Published in: Journal of hematology & oncology (2019)
Clinical Trial ID: NCT02836795 , registered July 19, 2016, retrospectively registered.
Keyphrases
  • clinical trial
  • phase ii
  • open label
  • study protocol
  • double blind
  • randomized controlled trial
  • skin cancer
  • phase iii
  • basal cell carcinoma